Envisagenics is a biotechnology company focused on the discovery and development of novel RNA splicing therapeutics using artificial intelligence (AI). Founded as a spinout from Cold Spring Harbor Laboratory in 2014, the company is based in New York City. Envisagenics has raised significant funding, including a recent Series B round. It was co-founded by Maria Luisa Pineda and Martin Akerman. The company utilizes its proprietary AI platform, SpliceCore, to identify novel drug targets, partnering with leading pharmaceutical companies to enhance drug discovery capabilities.
| Attribute | Information |
|---|---|
| Founding Date | 2014 |
| Headquarters | New York City, New York, United States |
| Founders | Maria Luisa Pineda, Martin Akerman |
| Revenue | Non-disclosed |
| Profits | Non-disclosed |
| Key Investors | Bristol Myers Squibb, Third Kind Venture Capital |
| Industry | Biotechnology |
| Number of Employees | 51 - 100 |
Envisagenics was founded in 2014 by Maria Luisa Pineda and Martin Akerman, leveraging their experience at Cold Spring Harbor Laboratory. The company was inspired by the success of the RNA therapeutic Spinraza, which motivated the founders to further explore RNA splicing as a therapeutic target. The company's flagship AI platform, SpliceCore, was developed to enhance the drug discovery process by identifying splicing-derived targets. Envisagenics' early focus was on building collaborations with academic institutions and pharmaceutical companies, allowing it to validate its AI platform and secure initial funding, including non-dilutive SBIR grants.
Envisagenics has developed a robust business model centered around its AI-powered SpliceCore platform. This technology allows for the rapid identification of RNA splicing variants that can serve as novel drug targets. The company has secured partnerships with major pharmaceutical players such as Bristol Myers Squibb, Biogen, and Johnson & Johnson to address complex therapeutic challenges in oncology and other diseases.
Envisagenics focuses on utilizing AI and RNA sequencing data to accelerate therapeutic discovery and development. Its platform, SpliceCore, analyzes a vast database of RNA splicing events, reducing the time and cost of drug development. The company's strategic partnerships with leading biopharmaceutical firms position it at the forefront of innovation in RNA-based therapeutics. Envisagenics is recognized as a key player in the global AI-driven drug discovery market, with a strong focus on oncology and a growing interest in other diseases.
Envisagenics is a prominent player in the biotech industry, particularly in the field of RNA splicing therapeutics. By leveraging its expertise in AI and machine learning, the company has developed a sophisticated platform to identify novel drug targets, contributing to more efficient and effective drug discovery. Moving forward, Envisagenics aims to continue expanding its therapeutic pipeline and enhancing its strategic partnerships. With significant investment and support from major industry players, Envisagenics is poised for continued impact and growth within the biotechnology sector.